Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer

Cancer Invest. 2009 Oct;27(8):844-50. doi: 10.1080/07357900902744502.

Abstract

CD133, CD44, and CD166 are cell surface markers that have recently been associated with colorectal cancer stem cells. As which of these markers has the greatest impact on patient prognosis is currently unknown, we compared their expression and prognostic significance in 110 colorectal adenocarcinomas. We demonstrate that expression of CD133 correlates with that of CD166, while both do not correlate with CD44. We show that CD133 is the best sole marker to predict low patient survival, while the combined analysis of all three markers may be superior in identification of low-, intermediate-, and high-risk cases of colorectal cancer.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Adenocarcinoma / immunology*
  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD / analysis*
  • Biomarkers, Tumor / analysis*
  • Cell Adhesion Molecules, Neuronal / analysis*
  • Colorectal Neoplasms / immunology*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / therapy
  • Female
  • Fetal Proteins / analysis*
  • Glycoproteins / analysis*
  • Humans
  • Hyaluronan Receptors / analysis*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplastic Stem Cells / immunology*
  • Peptides / analysis*
  • Predictive Value of Tests
  • Proportional Hazards Models
  • Risk Assessment
  • Time Factors
  • Treatment Outcome

Substances

  • AC133 Antigen
  • ALCAM protein, human
  • Antigens, CD
  • Biomarkers, Tumor
  • CD44 protein, human
  • Cell Adhesion Molecules, Neuronal
  • Fetal Proteins
  • Glycoproteins
  • Hyaluronan Receptors
  • PROM1 protein, human
  • Peptides